Effects of Pneumococcal Conjugate Vaccine 2 Years after Its Introduction, the Netherlands

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Rodenburg, Gerwin D. ; de Greeff, Sabine C. ; Jansen, Angelique G.C.S. ; de Melker, Hester E. ; Schouls, Leo M. ; Hak, Eelko ; Spanjaard, Lodewijk ; Sanders, Elisabeth A.M. ; van der Ende, Arie
• Description:
  In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval CI 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.
• Subjects:
  • Research
  • Heptavalent Pneumococcal Conjugate Vaccine
  • Pneumococcal Vaccines
  • Pneumococcal Infections
  • Surveillance
  • Bacteria
  • Adolescent
  • Adult
  • Age Factors
  • Aged
  More +
• Source:
  Emerg Infect Dis. 16(5):816-823.
• Document Type:
  Journal Article
• Volume:
  16
• Issue:
  5
• Download URL:
  https://stacks.cdc.gov/view/cdc/18055/cdc_18055_DS1.pdf
• File Type:
  [PDF - 271.87 KB]
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:2db1a2d22003fbad0ef902954b720c01df110fd05d08b2e731f131decda336a8